Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Treasury Shares: 2013-2024

  • Coherus Oncology's Treasury Shares fell 55.51% to $768,237 in Q4 2024 from the same period last year, while for Dec 2024 it was $768,237, marking a year-over-year decrease of 55.51%. This contributed to the annual value of $768,237 for FY2024, which is 55.51% down from last year.
  • As of Q4 2024, Coherus Oncology's Treasury Shares stood at $768,237, which was down 55.51% from $1.7 million recorded in Q4 2023.
  • In the past 5 years, Coherus Oncology's Treasury Shares ranged from a high of $2.3 million in Q4 2022 and a low of $768,237 during Q4 2024.
  • For the 3-year period, Coherus Oncology's Treasury Shares averaged around $1.6 million, with its median value being $1.7 million (2023).
  • As far as peak fluctuations go, Coherus Oncology's Treasury Shares soared by 863.87% in 2020, and later crashed by 55.51% in 2024.
  • Quarterly analysis of 5 years shows Coherus Oncology's Treasury Shares stood at $1.0 million in 2020, then surged by 82.61% to $1.8 million in 2021, then grew by 26.55% to $2.3 million in 2022, then decreased by 26.00% to $1.7 million in 2023, then tumbled by 55.51% to $768,237 in 2024.
  • Its Treasury Shares stands at $768,237 for Q4 2024, versus $1.7 million for Q4 2023 and $2.3 million for Q4 2022.